VNRX VOLITIONRX LTD
In Vitro & In Vivo Diagnostic Substances · NYSE · SEC CIK 93314 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY134.0%
TTM net income YoY-3.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR74.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-512.6%
Net margin-698.5%
FCF margin-597.6%
EBITDA margin-489.2%
Returns
ROE—
ROA-352.5%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets481.7%
Debt / equity—
Current ratio0.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-51.9%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.73M | $1.23M | $775,302 | $306,392 | $90,035 |
| R&D expense | $10.08M | $14.41M | $19.55M | $15.33M | $13.02M |
| SG&A expense | $9.46M | $8.49M | $10.37M | $10.18M | $11.68M |
| Operating income | -$21.74M | -$27.02M | -$35.99M | -$31.78M | -$28.33M |
| Interest expense | — | — | — | — | $155,803 |
| Net income | -$23.36M | -$26.97M | -$35.68M | -$30.60M | -$26.99M |
| EBITDA | -$20.75M | -$25.91M | -$34.84M | -$30.84M | -$27.39M |
| EPS (basic) | — | — | — | — | -0.51 |
| EPS (diluted) | — | -0.31 | -0.50 | — | -0.51 |
| Weighted avg. shares (diluted) | 106.83M | 86.53M | 71.23M | — | 52.66M |
| Balance sheet | |||||
| Cash & equivalents | $1.12M | $3.26M | $20.73M | $10.87M | $20.58M |
| Receivables | $317,808 | $110,574 | $242,617 | $72,609 | $12,510 |
| Current assets | $2.06M | $4.06M | $21.85M | $12.17M | $21.98M |
| PP&E, net | $4.03M | $4.43M | $5.52M | $5.39M | $4.91M |
| Intangibles | $316,704 | $313,747 | $23,886 | $110,505 | $216,876 |
| Total assets | $6.90M | $9.40M | $27.95M | $18.30M | $27.49M |
| Current liabilities | $12.23M | $7.79M | $8.94M | $17.39M | $6.52M |
| Short-term debt | $890,571 | $860,223 | $1.21M | $1.07M | $797,855 |
| Long-term debt | $5.82M | $3.95M | $3.62M | $2.78M | $2.27M |
| Total debt | $6.71M | $4.81M | $4.83M | $3.85M | $3.07M |
| Total liabilities | $42.49M | $35.51M | $36.66M | $21.42M | $9.77M |
| Shareholders' equity | -$34.25M | -$24.91M | -$7.80M | -$2.57M | $17.72M |
| Net debt | $5.59M | $1.55M | -$15.90M | -$7.02M | -$17.51M |
| Shares outstanding | 6.29M | 96.10M | 81.90M | 57.87M | 53.77M |
| Cash flow statement | |||||
| Operating cash flow | -$19.68M | -$25.89M | -$18.06M | -$15.28M | -$20.85M |
| Capital expenditure | $89,558 | $277,499 | $1.08M | $1.57M | $973,559 |
| Free cash flow | -$19.77M | -$26.17M | -$19.15M | -$16.85M | -$21.83M |
| Investing cash flow | -$89,558 | -$573,852 | -$1.08M | -$1.57M | -$973,559 |
| Financing cash flow | $17.09M | $8.66M | $28.98M | $6.94M | $22.86M |
| Depreciation & amortization | $983,706 | $1.11M | $1.15M | $936,084 | $945,367 |
| Stock-based compensation | $1.74M | $1.27M | $2.29M | $3.11M | $2.45M |
| Share buybacks | — | $0 | $31,772 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.